Patents Examined by Joseph G Dauner
  • Patent number: 10538804
    Abstract: Described herein are methods and devices for nucleic acid quantification and, in particular, to microfluidic methods and devices for nucleic acid quantification. In certain embodiments methods of quantifying a target nucleic acid without the need for amplification are provided. The methods involve, in some embodiments, allowing a binding agent to become immobilized with respect to the target nucleic acid. In some cases, the binding agent comprises a signaling moiety that can be used to quantify the amount of target nucleic acid. In another aspect, the quantification can be carried out rapidly. For example, in certain embodiments, the quantification can be completed within 5 minutes. In yet another aspect, samples containing a low amount of target nucleic acid can be quantified. For instance, in some cases, samples containing less than 100 nanograms per microliter may be quantified. Also described are devices and kits for performing such methods, or the like.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: January 21, 2020
    Assignee: ANDE Corporation
    Inventors: Eugene Tan, Richard F. Selden, Rosemary S. Turingan
  • Patent number: 10533213
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 14, 2020
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Patent number: 10533223
    Abstract: The present invention provides detection systems and methods for detection of loci and genomic regions in a sample, including mixed samples, using hybridization to an array.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: January 14, 2020
    Assignee: Ariosa Diagnostics, Inc.
    Inventors: Arnold Oliphant, Jacob Zahn, Kara Juneau, Patrick Bogard, Stephanie Huang
  • Patent number: 10533210
    Abstract: The present invention is based on the discovery of sensitive and specific methylation detection by a) controlling excessive DNA degradation prior to conversion by incubating DNA conversion reagent (e.g. bisulfite reagent) directly with a nucleic acid containing sample without requiring prior nucleic acid purification from the sample and without requiring prior nucleic acid denaturation at elevated temperatures of 98° C. and, b) optimizing bisulfite removal by controlling the pumping rate flow of the bisulfite treated sample over an extraction membrane inside an automated system.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 14, 2020
    Assignee: Biocartis NV
    Inventors: David Nauwelaers, Hannah Kenens
  • Patent number: 10525459
    Abstract: An apparatus for sequencing a nucleic acid by printing droplets at least some of which contain single nucleotides derived from the nucleic acid is provided.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: January 7, 2020
    Assignee: BASE4 INNOVATION LTD
    Inventors: Cameron Alexander Frayling, Thomas Henry Isaac
  • Patent number: 10519497
    Abstract: A method of analysing a single nucleoside triphosphate comprising: (1) producing at least one substantially double-stranded oligonucleotide used probe by reacting in the presence of a polymerase and a ligase the single nucleoside triphosphate with a corresponding probe system comprising (a) a first single-stranded oligonucleotide labelled with detectable elements in an undetectable state and (b) second and third single-stranded oligonucleotides capable of hybridising to complementary regions on the first oligonucleotide; (2) digesting the used probe with an enzyme having double-stranded exonucleolytic activity to yield the detectable elements in a detectable state and a single-stranded fourth oligonucleotide which is at least in part the sequence complement of the first oligonucleotide; (3) reacting the fourth oligonucleotide with another first oligonucleotide to produce a substantially double-stranded oligonucleotide product corresponding to the used probe; (4) repeating steps (2) and (3) in a cycle and (5)
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: December 31, 2019
    Assignee: BASE4 INNOVATION LTD
    Inventors: Barnaby Balmforth, Cameron Alexander Frayling
  • Patent number: 10519508
    Abstract: The present invention relates to a method for classifying a diffuse large B-cell lymphoma (DLBCL) of a subject into a GCB-DLBCL or into a ABC-DLBCL comprising the step of determining the expression level of 10 genes in a tumor tissue sample obtained from the subject by performing a Reverse Transcriptase Multiplex Ligation dependent Probe Amplification (RT-MLPA) assay wherein the 10 genes are NEK6, IRF4, IGHM, LMO2, FOXP1, TNFRSF9, BCL6, TNFRSF13B, CCND2 and MYBL1.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: December 31, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Rouen, Centre Henri Becquerrel
    Inventors: Fabrice Jardin, Philippe Ruminy, Sylvain Mareschal, Vinciane Marchand, Cristina Bagacean
  • Patent number: 10513745
    Abstract: Provided herein is an internal standard method for determining copy number of a pathogen DNA in an unpurified nucleic acid sample by using a known copy number of synthetic DNA that shares a consensus region sequence with the pathogen. The sample is subject to two amplification steps using locus-specific primers and fluorescent primers respectively to obtain fluorescent amplicons for the pathogen and synthetic DNA. These are hybridized with immobilized pathogen-specific and synthetic DNA-specific nucleic acid probes and imaged to obtain fluorescent signals for pathogen-specific and synthetic DNA-specific amplicons. Signal intensities are correlated with the known copy number of synthetic DNA to determine copy number of pathogen DNA in the plant. Also described herein is a method to simultaneously quantitate using the above method, copy numbers of both pathogen and plant DNA in a sample.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: December 24, 2019
    Assignee: PathogenDX Inc
    Inventors: Michael Edward Hogan, Melissa Rose May, Frederick Henry Eggers
  • Patent number: 10508307
    Abstract: The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene DMBT1 is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene DMBT1 and optionally one or more further marker genes selected from KIAA1199, TMSB15A, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAM5, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: December 17, 2019
    Assignee: Transgenion—International Institute for Regenerative Translational Medicine GmbH
    Inventor: Rolf Ziesche
  • Patent number: 10508301
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: December 17, 2019
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Patent number: 10501795
    Abstract: A probe system comprising (a) a first single-stranded oligonucleotide labelled with detectable elements in an undetectable state, and (b) second and third single-stranded oligonucleotides capable of hybridising to complementary regions on the first oligonucleotide.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: December 10, 2019
    Assignee: BASE4 INNOVATION LTD
    Inventors: Barnaby Balmforth, Cameron Alexander Frayling
  • Patent number: 10501814
    Abstract: Provided herein is a dual amplification method for detecting plant pathogens by analysis of pathogen DNA in an unpurified nucleic acid sample from the plant. Pathogen-specific primers are used to generate a first set of amplicons that are further amplified in a second amplification step using fluorescent tagged pathogen-specific primers. Fluorescent amplicons thus generated are hybridized with pathogen-specific nucleic acid probes that are immobilized on a solid support using bifunctional polymer linkers. The hybridized microarray is imaged to obtain fluorescent images of the amplicons and the nucleic acid probes, which are superimposed to detect the pathogen present in the plant. Also described herein is a method to simultaneously detect both plant DNA and pathogen DNA in a single assay.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: December 10, 2019
    Assignee: PathogenDX Inc
    Inventors: Michael Edward Hogan, Melissa Rose May, Frederick Henry Eggers
  • Patent number: 10487353
    Abstract: Reaction mixture containing an analyte probe and an internal control probe, where the analyte probe and the internal control probe target different nucleic acids and have labels that generate signals that are indistinguishable from each other.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 26, 2019
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Sunghae A. Joo, Janel M. Dockter
  • Patent number: 10487360
    Abstract: The present invention provides a method for determining whether an individual with relapsing-remitting multiple sclerosis will suffer a relapse or respond to treatment for MS. A ratio of mRNA levels of Response Gene to Complement-32, FasL or IL-21 to L13 determined for an individual provides a normalized level which is compared to a cut-off value. A normalized level of Response Gene to Complement-32 greater than 2.52, a normalized level of FasL greater than 85.4 and a normalized level of IL-21 less than 11.9, respectively, indicates the individual will have or is having a relapse of multiple sclerosis. Also provided are methods for determining whether an individual will respond positively or is responding positively to glatiramer treatment and whether the individual is in a period of stable disease or is not at risk for relapse of multiple sclerosis by comparing normalized levels with the respective cut-off levels.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: November 26, 2019
    Assignees: University of Maryland, Baltimore, The Department of Veterans Affairs
    Inventors: Horea Rus, Cornelia Cudrici, Cosmin Tegla
  • Patent number: 10478816
    Abstract: The invention provides a passive fluidics circuit for directing different fluids to a common volume, such as a reaction chamber or flow cell, without intermixing or cross contamination. The direction and rate of flow through junctions, nodes and passages of the fluidics circuit are controlled by the states of upstream valves (e.g. opened or closed), differential fluid pressures at circuit inlets or upstream reservoirs, flow path resistances, and the like. Free diffusion or leakage of fluids from unselected inlets into the common outlet or other inlets at junctions or nodes is prevented by the flow of the selected inlet fluid, a portion of which sweeps by the inlets of unselected fluids and exits the fluidics circuit by waste ports, thereby creating a barrier against undesired intermixing with the outlet flow through leakage or diffusion. The invention is particularly advantageous in apparatus for performing sensitive multistep reactions, such as pH-based DNA sequencing reactions.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: November 19, 2019
    Assignee: Life Technologies Corporation
    Inventors: Jonathan Schultz, David Marran
  • Patent number: 10471428
    Abstract: Fluidic devices with a primary transport nanochannel(s) intersected by at least one nanoscale manifold for active control of capture, manipulation and transport of analyte molecules. The at least one manifold can be an array or network of nanochannels, nanoslits or nanoelectrodes joined to a common voltage or pressure source. A respective nanoscale manifold can be configured to allow for precise and active control of driving forces applied to the primary transport nanochannel(s) to drive molecular transport through the various regions along the transport nanochannel(s). The at least one manifold can generate monotonic force gradients with a limited or reduced number of independent input potentials and/or pressures applied to the device.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: November 12, 2019
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: John Michael Ramsey, Laurent D. Menard, Michael A. Tycon, Oscar A. McCrate
  • Patent number: 10472666
    Abstract: The present disclosure provides a system and method for depleting target nucleic acids from a nucleic acid sample. In one aspect, a kit according to the present disclosure includes a plurality of DNA probes. Each of the DNA probes is hybridizable to form a heteroduplex with at least one of a plurality of target RNA transcripts in a nucleic acid sample. The number of unique target RNA transcripts hybridized by the plurality of DNA probes is at least three. The kit further includes an enzyme having RNA-DNA hybrid ribonucleotidohydrolase activity, where degrades at least the RNA portion of the heteroduplex.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: November 12, 2019
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Venera Bouriakov, Daniel Burgess
  • Patent number: 10466159
    Abstract: The present disclosure relates to a system, method, and kit for particle detection and analysis. Devices disclosed herein may include at least an optical source, a fluidic chip containing a multiplex bead array, and a detection module, wherein the sample flows within the fluidic chip past a detection window, where the cells or particles are imaged by an image acquisition and analysis module that may include an optical detector. The image acquisition and analysis module counts the labeled particles and software allows for analysis of bead population.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: November 5, 2019
    Assignee: ChipCare Corporation
    Inventors: James Jiahua Dou, Lu Chen, James Andrew Fraser, Rakesh Kumar Nayyar
  • Patent number: 10443091
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: October 15, 2019
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Patent number: 10435735
    Abstract: Methods, compositions, and kits for stabilizing both human and microbial deoxyribonucleic acid (DNA) present in complex biological samples, such as feces, are disclosed. In particular, aqueous compositions for stabilizing DNA contained in biological samples at ambient temperature are disclosed, together with associated methods and kits using same. In one aspect, the compositions comprise a chelating agent present at a concentration of at least about 150 mM, and the composition has a pH of at least about 9.5.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: October 8, 2019
    Assignee: DNA GENOTEK INC.
    Inventors: Hyman Chaim Birnboim, Lindsay Pozza, Carlos Alberto Merino Hernandez, Evgueni Vladimirovitch Doukhanine